NEW YORK, NY / ACCESSWIRE / December 6, 2017 / A surprise patent win for Biocept help shares climb to a close of 70% in gains while positive phase 2 clinical data on its NSI-189 drug helped Neuralstem experience a massive breakout in the triple digits yesterday.

RDI Initiates Coverage on:

Neuralstem, Inc.
http://www.rdinvesting.com/report/?ticker=CUR

Biocept, Inc.
http://www.rdinvesting.com/report/?ticker=BIOC

Neuralstem, Inc. shares were explosive on Tuesday, closing the day up a staggering 175.89%. The stock was one of the biggest gainers on the NASDAQ with trading volume of over 55 million skyrocketing past its average volume of just around 490,000 shares. The big gains came after the company announced successful updated phase 2 clinical data on its NSI-189 drug. According to the data, the 40 mg dose of the drug achieved statistical significance against the placebo and showed efficacy and antidepressant impacts for NSI-189. The data was revealed in a presentation entitled "A Phase 2, Double-Blind, Placebo-Controlled Study of NSI-189 Phosphate, a Neurogenic Compound, Among Out-Patients with Major Depressive Disorder." Maurizio Fava, MD, the principal investigator on the trial remarked, "NSI-189 appears to be a broad-acting antidepressant, with effects in both core symptoms of depression and in aspects of cognition where standard antidepressants typically show very modest effects. These results warrant the continued study of this compound among MDD patients who are inadequately managed by current antidepressant therapies."

Access RDI's Neuralstem, Inc. Research Report at:
http://www.rdinvesting.com/report/?ticker=CUR

Biocept, Inc. shares closed up nearly 70% yesterday on a little over 11 million shares traded compared to an average trading volume of just around 327,000 shares. The stock saw big gains after it was revealed that the company has been issued a key US patent that covers its proprietary "switch-blocker" technology. Company CSO Lyle Arnold stated "The issuance of this patent signals what we believe is the first in a series of worldwide patents protecting our proprietary, highly sensitive ctDNA platform technology [...] When combined with our patents and technology related to CTC capture and analysis as well as our blood transport tubes, Biocept has significant coverage protecting all three of its core liquid biopsy technology platforms." CEO Michael Nall also remarked, "Biocept remains differentiated in the liquid biopsy field by using both ctDNA and CTC analysis on patient samples to detect and monitor actionable cancer biomarkers that are listed in the NCCN guidelines. Both of our platform technologies offer specialized enrichment methods that can aid physicians in making more informed decisions in the treatment of their patients with cancer. Obtaining this new intellectual property provides additional patent protection for the unique and novel features of our Target Selector? dual-platform approach."

Access RDI's Biocept, Inc. Research Report at:
http://www.rdinvesting.com/report/?ticker=BIOC

Our Actionable Research on Neuralstem, Inc. (NASDAQ: CUR) and Biocept, Inc. (NASDAQ: BIOC) be downloaded free of charge at Research Driven Investing.

Research Driven Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and reviewed by Nadia Noorani, CFA® charter holder. RDInvesting.com is neither a registered broker-dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com